160 related articles for article (PubMed ID: 34290990)
1. Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas.
Mehta S; Bhimani N; Gill AJ; Samra JS; Sahni S; Mittal A
Front Oncol; 2021; 11():708963. PubMed ID: 34290990
[TBL] [Abstract][Full Text] [Related]
2. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
3. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas.
Hipperson L; Hadden WJ; Nahm CB; Gill AJ; Samra JS; Dona A; Mittal A; Sahni S
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129966. PubMed ID: 34329704
[TBL] [Abstract][Full Text] [Related]
4. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer.
Sahni S; Moon EA; Howell VM; Mehta S; Pavlakis N; Chan D; Ahadi MS; Gill AJ; Samra J; Mittal A
Eur J Surg Oncol; 2020 Aug; 46(8):1539-1542. PubMed ID: 32061458
[TBL] [Abstract][Full Text] [Related]
5. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
8. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
9. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
12. Serum biomarker panels for the detection of pancreatic cancer.
Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.
Kruger D; Lahoud N; Yako YY; Devar J; Smith M
PLoS One; 2022; 17(1):e0262439. PubMed ID: 35020761
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas.
Mehta S; Bhimani N; Gill AJ; Samra JS; Sahni S; Mittal A
Front Oncol; 2021; 11():774861. PubMed ID: 34692555
[TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
18. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
20. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
